Sign In
Buy BVS
Bioventus Earnings Calls
| Release date | May 06, 2026 |
| EPS estimate | $0.0900 |
| EPS actual | $0.150 |
| EPS Surprise | 66.67% |
| Revenue estimate | 129.915M |
| Revenue actual | 132.089M |
| Revenue Surprise | 1.67% |
| Release date | Mar 05, 2026 |
| EPS estimate | $0.220 |
| EPS actual | $0.240 |
| EPS Surprise | 9.09% |
| Revenue estimate | 154.948M |
| Revenue actual | 157.9M |
| Revenue Surprise | 1.91% |
| Release date | Nov 04, 2025 |
| EPS estimate | $0.215 |
| EPS actual | $0.150 |
| EPS Surprise | -30.23% |
| Revenue estimate | 155.701M |
| Revenue actual | 138.651M |
| Revenue Surprise | -10.95% |
| Release date | Aug 06, 2025 |
| EPS estimate | $0.220 |
| EPS actual | $0.210 |
| EPS Surprise | -4.55% |
| Revenue estimate | 138.778M |
| Revenue actual | 147.66M |
| Revenue Surprise | 6.40% |
Last 4 Quarters for Bioventus
Below you can see how BVS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 06, 2025 |
| Price on release | $7.29 |
| EPS estimate | $0.220 |
| EPS actual | $0.210 |
| EPS surprise | -4.55% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $6.52 |
| Aug 01, 2025 | $6.18 |
| Aug 04, 2025 | $6.32 |
| Aug 05, 2025 | $6.14 |
| Aug 06, 2025 | $7.29 |
| Aug 07, 2025 | $6.93 |
| Aug 08, 2025 | $6.92 |
| Aug 11, 2025 | $6.93 |
| Aug 12, 2025 | $7.31 |
| 4 days before | 11.81% |
| 4 days after | 0.274% |
| On release day | -4.94% |
| Change in period | 12.12% |
| Release date | Nov 04, 2025 |
| Price on release | $7.55 |
| EPS estimate | $0.215 |
| EPS actual | $0.150 |
| EPS surprise | -30.23% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $6.77 |
| Oct 30, 2025 | $6.77 |
| Oct 31, 2025 | $6.55 |
| Nov 03, 2025 | $6.56 |
| Nov 04, 2025 | $7.55 |
| Nov 05, 2025 | $7.38 |
| Nov 06, 2025 | $7.48 |
| Nov 07, 2025 | $7.45 |
| Nov 10, 2025 | $7.49 |
| 4 days before | 11.52% |
| 4 days after | -0.795% |
| On release day | -2.25% |
| Change in period | 10.64% |
| Release date | Mar 05, 2026 |
| Price on release | $9.10 |
| EPS estimate | $0.220 |
| EPS actual | $0.240 |
| EPS surprise | 9.09% |
| Date | Price |
|---|---|
| Feb 27, 2026 | $8.78 |
| Mar 02, 2026 | $8.77 |
| Mar 03, 2026 | $8.74 |
| Mar 04, 2026 | $8.47 |
| Mar 05, 2026 | $9.10 |
| Mar 06, 2026 | $8.41 |
| Mar 09, 2026 | $8.61 |
| Mar 10, 2026 | $8.86 |
| Mar 11, 2026 | $8.90 |
| 4 days before | 3.64% |
| 4 days after | -2.20% |
| On release day | -7.58% |
| Change in period | 1.37% |
| Release date | May 06, 2026 |
| Price on release | $10.92 |
| EPS estimate | $0.0900 |
| EPS actual | $0.150 |
| EPS surprise | 66.67% |
| Date | Price |
|---|---|
| Apr 30, 2026 | $9.87 |
| May 01, 2026 | $10.11 |
| May 04, 2026 | $10.17 |
| May 05, 2026 | $10.68 |
| May 06, 2026 | $10.92 |
| May 07, 2026 | $10.65 |
| May 08, 2026 | $10.50 |
| May 11, 2026 | $10.19 |
| May 12, 2026 | $10.14 |
| 4 days before | 10.64% |
| 4 days after | -7.14% |
| On release day | -2.47% |
| Change in period | 2.74% |
Bioventus Earnings Call Transcript Summary of Q1 2026
Bioventus reported a solid start to 2026 with Q1 revenue of $132M, up 7% year-over-year, and adjusted EBITDA of $24M, up 24% (adjusted EBITDA margin expanded to 18%). Adjusted EPS was $0.15 (nearly double year-ago). Cash from operations improved by ~$28M versus prior-year Q1 to $9M; the company ended the quarter with $36M cash and $272M of debt after paying down $22M. Management reaffirmed 2026 revenue guidance of $600–$610M, and raised adjusted EPS guidance to $0.75–$0.79 and cash from operations guidance to $84–$89M. Bioventus is increasing targeted investments (roughly $13M planned for the year, ramping after Q1) into four growth drivers—PNS (largest share of investment), PRP, Ultrasonics, and International—while aiming to keep adjusted EBITDA margin around 20% for the year. They hired Megan Rosengarten as GM of PNS, expect PRP+PNS to contribute ~200 basis points to growth in 2026, and plan to reach net leverage below 2x by end of Q2 2026 (ahead of schedule), creating additional interest savings and capital allocation optionality. Management emphasized continued commercial/medical education investments to accelerate adoption (notably for Ultrasonics and PNS) and expects revenue and profitability acceleration in H2 as investments scale.
